Lilly to Acquire Atai Life Sciences for $2.8B Upfront Plus CVR
Eli Lilly will acquire Atai Life Sciences for $6.75 per share in cash plus up to $2.50 per share in contingent value rights, valuing the deal at $2.8 billion upfront with potential additional $1 billion. The transaction is expected to close in the third quarter, subject to regulatory approvals.
Eli Lilly (LLY) announced it will acquire Atai Life Sciences (ATAI) in a deal valued at $2.8 billion upfront, with up to $1 billion in contingent value rights (CVRs).
Under the terms, Atai shareholders will receive $6.75 per share in cash plus up to $2.50 per share in CVRs. The acquisition is intended to advance therapies for treatment-resistant depression and other mental health conditions.
The transaction is expected to close in the third quarter of 2025, subject to customary closing conditions and regulatory approvals.
Source: First Squawk